Evidence map›Paper›PMID 33102398›Full record

ArticleCanadian journal of gastroenterology & hepatology2020

Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option.

Antonella Argentiero, Angela Calabrese, Angela Monica Sciacovelli, Sabina Delcuratolo, Antonio Giovanni Solimando, Oronzo Brunetti

2 registry-linked trialsOpen access · goldAbstract readCase Reports
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00855634 naterminatednot on this map

Extended Versus Standard Resection in Two Cohorts of Patients With Adenocarcinoma of the Pancreas: Minimal Metastatic Disease or Venous Infiltration - a Randomized Trial

TypeinterventionalSponsorTechnical University of MunichRan2009 to 2012Enrolled355ConditionsPancreatic CancerArmsResection of metastases, Resection of infiltrated veins
NCT02892305 active not recruitingnot on this map

Hepatic Resection for Metastatic Pancreatic Cancer

TypeobservationalSponsorDuke UniversityRan2018 to 2027Enrolled18ConditionsPancreatic Neoplasms, Neoplasm Metastasis, Liver MetastasesArmsHepatic Resection or Ablation with Pancreaticoduodenectomy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Antonella ArgentieroMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Angela CalabreseRadiology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Angela Monica SciacovelliMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Sabina DelcuratoloMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Antonio Giovanni SolimandoMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.ORCID 0000-0002-2293-9698
Oronzo BrunettiMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.ORCID 0000-0002-7014-6828
Istituto Tumori Bari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor. What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we reported a case of a patient with PDAC of the head with multiple liver metastases, who underwent first-line chemotherapy with mFOLFIRINOX. After 10 cycles, he achieved a complete radiological response of liver metastases and a partial response of pancreatic lesion. A duodenocephalopancreasectomy was performed. Due to liver a lung metastases after 8 months from surgery, a second-line therapy was started with a disease-free survival and overall survival of 8 months and 45 months, respectively. Improvement in the molecular characterization of PDAC could help in the selection of patients suitable for multimodal treatments. This trial is registered with NCT02892305 and NCT00855634.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalLiver NeoplasmsPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle Aged

Identifiers

PMID33102398
PMCPMC7569435
OpenAlexW2970895823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.